Supplementary Methods from AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations

Katharine Yen, Shinsan M. Su, Fang Wang et al.|Unknown|2023

Cited by 0